Sodium-glucose co-transporter (SGLT) inhibitors are a new group of oral medications used for treating type 2 diabetes. Dapagliflozin was approved in January 8 th , 2014 and is the second selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) to be marketed in the US. It is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 Diabetes Mellitus (T2DM).It is available 5mg and 10 mg in film coated tablets. It acts by inhibiting SGLT2 decreases plasma glucose by increasing urinary glucose excretion. The common adverse reactions are genital mycotic infection, nasopharyngitis, urinary tract infections, back pain, urination increase, nausea, influenza. It is contraindicated in hypertension, renal impairment, hypoglycemia, genital myotic infections and bladder cancer.
INTRODUCTION:

SGLT Inhibitors
• Sodium-glucose co-transporter (SGLT) inhibitors are a new group of oral medications used for treating type 2 diabetes.
• The drugs work by helping the kidneys to lower blood glucose levels.
• SGLT inhibitors have been approved for the treatment of Type 2 diabetes since 2013. They are taken once a day with or without food.
•
The following drugs belong to the SGLT inhibitors class: GENERIC NAME TRADE NAME COMPANY • Monitor for signs and symptoms after initiating therapy.
Impairment in renal function
• Dapagliflozin increases serum creatinine and decreases eGFR.
• Elderly patients and patients with impaired renal function may be more susceptible to these changes.
•
Evaluate renal function prior to initiating dapagliflozin and periodically thereafter.
Hypoglycemia
• The risk of hypoglycemia can be increased when dapagliflozin is combined with insulin or insulin secretagogues (e.g., sulfonylureas).
• A lower dose of insulin or insulin secretagogue may be needed to minimize the risk.
Genital mycotic infections
• Dapagliflozin increases the risk of genital mycotic infections.
•
Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections.
Bladder Cancer
• There are insufficient data to determine if dapagliflozin has an effect on pre-existing bladder tumors.
•
Dapagliflozin should not be used in patients with active bladder cancer.
In those with a prior history of bladder cancer, the product labeling states that risk versus benefit be considered.
Pregnancy and Nursing
• Pregnancy Category C • In rat studies, dapagliflozin may affect renal development and maturation.
•
The timing of these effects corresponds to 2 nd and 3 rd trimester of human development; therefore consider alternate therapy during pregnancy especially during the 2nd and 3rd trimester.
• Dapagliflozin is secreted in milk of lactating rats.
• It is not known if dapagliflozin is excreted in human milk.
Because of the potential for serious adverse reactions to the nursing infant, a decision should be made to discontinue dapagliflozin or nursing taking into account the importance of the drug to the mother.
Storage
Store at room temperature in between 20 to 25 degree centigrade.
